Company Overview and News

 
Cummins India Limited - Clarification - Financial Results

2018-05-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Cummins India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Cummins India Limited - Change in Director(s)

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Cummins India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Cummins India Limited - Updates

2018-05-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Ravi Venkatesan resigns as independent director of Infosys

2018-05-11 moneycontrol
Infosys Ltd announced on Friday that Ravi Venkatesan, Independent Director, would step down from the company's board to accept "an exciting new role".

 
Broker's call

2018-05-03 thehindubusinessline
Both global giants in diesel engine business, Cummins Inc and Caterpillar reported strong results as sales grew by 21 per cent and 31 per cent respectively and both companies increased their annual growth guidance. For Cummins Inc the growth in power generation business was driven by North America and Asian markets, while Caterpillar reported healthy growth in Europe, Africa and West Asia (EAME) region.

 
Infra stocks see investor interest revival

2018-04-04 thehindubusinessline
Priya Kansara After a prolonged period of stepmotherly treatment towards infrastructure stocks for a plethora of reasons, sentiment towards them has been finally changing in a positive way. In other words, infrastructure stocks are again gaining investor interest after a long hiatus.

 
TPG Capital, Blackstone Group vie for Kirloskar Oil Engines

2018-03-30 livemint
Mumbai: Global private equity funds Blackstone Group Lp and TPG Capital are in separate discussions to acquire a controlling stake in Kirloskar Oil Engines Ltd, two people aware of the development said.

 
Market Update: Broader indices stay in green as RIL, ONGC gain 1-2%; Indiabulls Ventures spikes 17%

2018-03-22 moneycontrol
The Indian markets on Thursday morning were trading on a positive note after the US Fed raised its interest rate by 25 basis points. The Nifty added 35 points or 0.35 percent while the Sensex was up 127 points.

 
Closing Bell: Sensex ends 74 pts higher but fails to hold 33K; Bharti Infratel up 5%

2018-03-20 moneycontrol
3:30 pm Market Closing: The market closed mildly higher amid volatility ahead of two-day US Federal Reserve meeting beginning later in the day.

 
Market Live: Sensex volatile ahead of US Fed meet; IOC falls for 5th day, ICICI dips

2018-03-20 moneycontrol
2:40 pm New Telecom Policy: Union Minister Manoj Sinha said the new telecom policy is almost ready and will be brought in the next session of Parliament after a Cabinet nod.

 
Cummins India Limited - Addendum

2018-03-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Market Live: Sensex holds morning gains ahead of US Fed meet; Cipla recovers

2018-03-20 moneycontrol
12:42 pm Market Update: The market continued to trade higher with the Sensex rising more than 100 points and was trading above the 33,000 levels. Investors looked for cues from the two-day US Federal Reserve meeting beginning later in the day.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...